FDA Panel Opposes Lowering BMI Criteria For Obesity Clinical Trials
This article was originally published in The Tan Sheet
Executive Summary
A majority of FDA's Endocrinologic & Metabolic Drugs Advisory Committee members recommended against lowering the body mass index for clinical trials involving weight-loss drugs